{
  "docId": "019de073-7087-77cd-a846-97dda09bac98",
  "docSlug": "031593eaf739f40f0f0c49214c912ed3",
  "documentTitle": "9 Meters Biopharma | Investor Presentation Deck | 30 slides",
  "authorId": "9-meters-biopharma",
  "authorName": "9 Meters Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 30,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7087-77cd-a846-97dda09bac98/8",
  "deckHref": "/decks/019de073-7087-77cd-a846-97dda09bac98",
  "deckJsonHref": "/decks/019de073-7087-77cd-a846-97dda09bac98.json",
  "deckAnchorHref": "/decks/019de073-7087-77cd-a846-97dda09bac98#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.105,
        "w": 0.86,
        "x": 0.065,
        "y": 0.23
      },
      "kind": "diagram",
      "text": "2022 timeline with 1H22 and 2H22 markers",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1109550-50c2-4456-a7c7-38150e0eaa6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.165,
        "y": 0.425
      },
      "kind": "list",
      "text": "1H22: Vurolenatide (SBS) Phase 2 trial preliminary results; Larazotide (celiac) Phase 3 trial interim analysis",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2eebd362-2990-4e2a-8ce7-5ce94170a6d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.525,
        "y": 0.425
      },
      "kind": "list",
      "text": "2H22: Vurolenatide (SBS) end-of-Phase 2 meeting with FDA; Vurolenatide (SBS) Phase 2 final results; Vurolenatide (SBS) Phase 3 protocol finalization; Vurolenatide (SBS) Phase 3 trial initiation; NM-102 progression toward IND; NM-136 progression toward IND",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b84a0b10-7d87-4d13-8734-06625d1ed48f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.044,
        "w": 0.355,
        "x": 0.076,
        "y": 0.148
      },
      "kind": "title",
      "text": "Near-term development milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb07fa2d-2ea0-4638-8265-67a768f25c15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "582d156d-76ac-4f8d-9d7e-8ce184e285a0",
      "evidence": "Timeline visualization of project milestones",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}